1. Home
  2. BCAL vs AKBA Comparison

BCAL vs AKBA Comparison

Compare BCAL & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Southern California Bancorp

BCAL

Southern California Bancorp

HOLD

Current Price

$18.43

Market Cap

616.3M

Sector

Finance

ML Signal

HOLD

Logo Akebia Therapeutics Inc.

AKBA

Akebia Therapeutics Inc.

HOLD

Current Price

$1.25

Market Cap

729.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BCAL
AKBA
Founded
2001
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
616.3M
729.1M
IPO Year
2020
2014

Fundamental Metrics

Financial Performance
Metric
BCAL
AKBA
Price
$18.43
$1.25
Analyst Decision
Buy
Strong Buy
Analyst Count
3
6
Target Price
$20.50
$5.75
AVG Volume (30 Days)
181.2K
3.4M
Earning Date
01-01-0001
05-27-2026
Dividend Yield
2.18%
N/A
EPS Growth
N/A
93.94
EPS
1.42
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$17.63
Revenue Next Year
$6.35
N/A
P/E Ratio
$12.92
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.88
$1.14
52 Week High
$20.47
$4.08

Technical Indicators

Market Signals
Indicator
BCAL
AKBA
Relative Strength Index (RSI) 44.06 43.18
Support Level $17.80 $1.14
Resistance Level $19.31 $1.57
Average True Range (ATR) 0.43 0.10
MACD -0.06 0.01
Stochastic Oscillator 42.99 22.83

Price Performance

Historical Comparison
BCAL
AKBA

About BCAL Southern California Bancorp

California BanCorp is a registered bank holding company headquartered in San Diego, California. The Bank offers a range of financial products and services to individuals, professionals, and small to medium-sized businesses through its 14 branch offices and four loan production offices serving Northern and Southern California. The Bank's solutions-driven, relationship-based approach to banking provides accessibility to decision-makers and enhances value through partnerships with its clients. The company has one operating segment: Commercial Banking.

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

Share on Social Networks: